MedTrace Logo

Anti-Mesothelin CAR-T Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors

NCT07010523 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-06-08

No results posted yet for this study

Summary

This is a single-arm, open-label, exploratory clinical study to evaluate the safety, tolerability and preliminary efficacy of Anti-Mesothelin CAR-T cell injection in patients with Mesothelin-positive advanced malignant solid tumors.

Conditions

  • Mesothelin-positive Advanced Malignant Solid Tumors

Interventions

BIOLOGICAL

Anti-mesothelin CAR-T cells

D0: 0.1×10\^6/Kg\~1.0×10\^6/Kg; cells will be infused intravenously.

DRUG

Fludarabine

D-7 to D-3: Fludarabine (25 mg/m\^2/day) will be administered intravenously for 5 days.

DRUG

Cyclophosphamide

D-7 to D-3: Cyclophosphamide (300 mg/m\^2/day) will be administered intravenously for 5 days.

Sponsors & Collaborators

  • UTC Therapeutics Inc.

    collaborator INDUSTRY

  • Zhejiang University

    lead OTHER

Principal Investigators

  • Weijia Fang, MD PhD · Zhejiang University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-15
Primary Completion
2026-10-14
Completion
2027-10-14

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07010523 on ClinicalTrials.gov